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INTRODUCTION
Obesity is a well-recognized risk factor for breast cancer 
(BC) in postmenopausal women. Studies indicate that all 
measures of obesity, such as waist to hip ratio (WHR), weight 
gain, body mass index (BMI), and percent body fat, are asso-
ciated with an increased risk of postmenopausal BC [1-4]. On 
the contrary, in premenopausal women, high body weight 
may be protective among women with fat accumulation in the 
lower body (low WHR) [5-7].
Obesity is also associated with a poorer prognosis and in-
creased mortality for patients with BC, which probably results 
from a diagnostic delay that leads to more advanced disease 
stages. Furthermore, BC in these patients is more aggressive 
because obesity is associated with the upregulation of a num-
ber of cellular proliferation pathways and is directly related to 
circulating estrogen levels. Moreover, obese patients are more 
likely to receive reduced doses of chemotherapy compared 
with normal-weight women [8-11].
Obesity and BC may have a considerable negative impact 
on public health. In the United States, it is estimated that 20% 
of all BC cases and up to 50% of deaths due to BC in post-
menopausal women can be attributed to obesity [12]. A pro-
spective study performed on an Italian population assessed 
the risk of BC in obese women according to biohumoral pa-
rameters such as glycemic index and area under the glucose 
response curve [13], but to our knowledge, there are no data 
focusing on the relationship between anthropometric vari-
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Purpose: We conducted a study to evaluate the relationship be-
tween body mass index (BMI) and the risk of breast cancer (BC) 
and outcome in a population of 14,684 women aged 55 to 69 
years eligible to participate in the Mammography Screening 
Program (MSP) in the Province of Modena, Italy. Methods: The 
study population was drawn from women who underwent mam-
mography screening between 2004 and 2006 in the Province of 
Modena. Women were subdivided into obese, overweight, and 
normal-weight categories according to BMI and followed until 
July 31, 2010, to evaluate the BC incidence. The clinicopathol-
ogical characteristics of BC were also evaluated in different 
groups of patients classified according to BMI. After BC diagno-
sis, patients were followed for a median period of 65 (range, 
2–104) months. Second events (recurrences and second tumors) 
were recorded, and the 5-year event-free survival (EFS) was cal-
culated. Results: After a period of 73 months, 366 cases of BC 
were diagnosed. Compared with normal-weight women, obese 
women had a significantly higher incidence of BC (relative risk 
[RR], 1.32; p=0.040) (RR=1), larger tumors (27% of tumors were 
larger than T2 size), and more nodal involvement (38.5% of 
tumors were node-positive). Furthermore, a significantly higher 
rate of total events was seen in obese women compared with 
overweight and normal-weight patients, respectively (17.9% vs. 
11.4% vs. 10.8%, p=0.032). The 5-year EFS was 89.0%, 
89.0%, and 80.0% for normal-weight, overweight, and obese 
patients, respectively. Conclusion: We observed a significantly 
higher risk of BC in obese women among those eligible to par-
ticipate in the MSP in the Province of Modena. Finally, obese 
women had more second events and poorer EFS compared to 
nono bese women.
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ables and the risk of BC in the Italian population. Further-
more, it is widely accepted that BMI is positively associated 
with several types of cancers including tumors of the colon 
and endometrium, adenocarcinoma of the esophagus, and 
kidney cancer [14]. Therefore, we conducted a study to evalu-
ate the relationship between BMI and BC incidence and out-
come (including relapses and second tumors) in a population 
of more than 14,500 women aged 55 to 69 years in the Prov-
ince of Modena, Italy.
METHODS
Study population 
The Mammography Screening Program (MSP) was started 
in 1995 in the Municipality of Modena and gradually extend-
ed to other districts of the province, with a population of 
701,500 inhabitants of which 358,134 are women.
Briefly, as established by the Italian National Health Service, 
all the asymptomatic women without palpable or clinical signs 
of breast lesions who were residents in the Province of Modena 
and aged 50 to 69 years were invited by letter to undergo a 
biannual bilateral two-view (i.e., lateral and oblique projec-
tions for right and left breast) screening mammogram. The 
screening mammogram was read by two radiologists; for sus-
picious findings, the patient was recalled for a second look, 
usually by ultrasound or by a focused radiogram, and a subse-
quent core or vacuum-assisted biopsy was performed to char-
acterize the lesion. In case of suspected or definitively diag-
nosed carcinoma, the patient underwent breast surgery and 
the final histology results were sent to the screening program 
and registered in a regional database.
The first screening round started in October 1995 and end-
ed in December 2001. Data on women invited to the MSP are 
registered and collected at the beginning and every 10 years. 
In the first round, 79,859 women were invited to participate in 
the MSP and 52,558 accepted (acceptance rate of 65.8%). Fur-
thermore, 1,458 women who were not invited were referred to 
the screening for breast symptoms (pain, discharge, or mass). 
The total recall rate for biopsy was 8.1 per 100,000 women 
with a detection rate of 10.2 per 100,000 women. Finally, 4,730 
women left the MSP after the first mammogram (abandon-
ment rate of 9.0%) (Table 1).
All of the women in this study were weighed, whereas 
heights were self-reported. BMI, defined as weight in kilo-
grams divided by height in meters squared (kg/m2), was cal-
culated only for women with complete height and weight 
data. Based on the BMI, women were grouped into the weight 
categories recommended by the World Health Organization 
(WHO) [15]: underweight (BMI < 18.5 kg/m2), normal-
weight (BMI= 18.5–24.9 kg/m2), overweight (BMI= 25–29.9 
kg/m2), and obese (BMI ≥ 30 kg/m2).
Our study population was drawn from women who under-
went mammography screening between July 1, 2004, and July 
31, 2006, and were followed until December 31, 2010. Because 
only anthropometric data that are part of regular clinical re-
cords were collected, the approval of the local ethical commit-
tee was not required. During the study period, 71,612 women 
underwent screening mammography, 36,607 of whom were 
55 to 69 years of age. All women were invited to participate in 
the study via an advertising campaign at the mammography 
screening site. Height and weight measurements were collect-
ed from all women who agreed to be weighed (15,702 wom-
en). We excluded women who had been diagnosed with an-
other cancer before or during the enrollment period (n =  
1,018). Therefore, the final study population consisted of 
14,684 women (Figure 1).
Table 1. Characteristics of population invited to breast cancer screen-
ing in province of Modena
Characteristic First round in 1996




Response rate (no. of invited respondents) (%) 65.8
Percentage no. of invited nonrespondents (%) 25.6
Total detection rate (×100,000) 10.2
Recall rate for biopsy (×100,000) 8.1














Accepted to be 
weighted
20,905
Refused to be 
weighted
Figure 1. Flow-chart of the study.
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The characteristics of the final study population, subdivided 
by age range and BMI, are reported in Table 2. Among 14,684 
women, 79 were underweight, 6,183 were normal-weight, 
5,762 were overweight, and 2,660 were obese. Baseline char-
acteristics regarding the remaining 20,905 women who were 
not weighed are lacking. However, considering a national pro-
spective study from the Italian Institute of Health in which 
women aged 50 to 69 years were randomly interviewed about 
their physical condition, 57.8% were overweight or obese, as 
in our sample [16].
Statistical analysis
Cancer cases were identified by record linkage with the 
Modena Cancer Registry (MCR). All the patients within the 
age range of 55 to 69 years diagnosed with BC in the period 
2004 to 2010 were selected from the MCR, which has operat-
ed since 1988 and collects all new cases of cancers occurring 
in residents of the Province of Modena, Italy. The Province of 
Modena, located in northern Italy, extends over 2,682 km2 
and has 47 municipalities. A cross-linkage between data from 
the MSP and MCR allowed the identification of cases with in-
vasive or in situ BC diagnosed at the MSP between July 1, 
2004, and December 31, 2010, with the last follow-up updated 
on December 31, 2012. All BC cases were identified as Inter-
national Classification of Disease (ninth revision, code 174). 
Cases diagnosed on the basis of a death certificate only were 
excluded; only microscopically confirmed cases were included 
for analysis. For every case, data on histology, staging at pre-
sentation (based on the 2009 Union for International Cancer 
Control Tumor-Node-Metastasis classification) [17], and 
treatment were obtained from clinical records. All the events 
(local or distant recurrence, second breast or nonbreast tu-
mors, and deaths from BC or from any other cause) that oc-
curred among these women during the follow-up period were 
retrieved by experienced clinical documentation clerks with 
active follow-up strategies.
The chi-square test was used to determine differences in 
clinic-pathological features between the BMI groups and be-
tween cases diagnosed in the study and screen-detected tu-
mors matched for age and calendar- period. We used a Pois-
son regression model to estimate relative risk (RR) and 95% 
confidence intervals (CIs) for overweight and obesity relative 
to normal BMI, adjusted for age and hormonal receptors. We 
believed that this model was suitable for a closed cohort like 
our population where a very low number of women migrate 
out of the Modena Province and the number lost to follow-up 
is negligible. Two distinct models were fitted, with BMI as a 
categorical variable or as a linear trend. Other variables, such 
as use of oral contraceptives or hormonal replacement thera-
py, age at menarche, parity, breastfeeding, or family history of 
BC were not evaluated in this model.
However, we subdivided BC cases according to selected 
clinicopathological characteristics obtained from the MCR 
database and we estimated the hazard ratio of BC incidence 
according to hormone receptor status between cases diag-
nosed in the study and screen-detected tumors matched for 
age and calendar-period. The Cox proportional hazards re-
gression model was used in multivariate analysis to determine 
whether the identified risk factors independently influenced 
incidence of BC. The covariates selected were BMI, tumor 
size, nodal involvement, and stage (I vs. others). The normal-
weight BMI group was used as the reference category to cal-
culate the RR. Hazard ratios and 95% exact and mid-p CIs 
were calculated and the Wald method was used to test for sig-
nificance.
The 5-year event-free survival (EFS) was defined as the time 
from diagnosis until the appearance of the first recurrence of 
BC or a second cancer. Survival was estimated by the Kaplan-
Meier method, and any differences in survival were evaluated 
with a stratified log-rank test.
We conducted the analysis using STATA (8.0 SE version) 
statistical package (StataCorp LP, College Station, USA). Dif-
ferences were considered statistically significant when the p-
value was ≤ 0.05. All statistical tests were two-sided.
RESULTS
Incidence of breast cancer
In total, 14,684 women were eligible for analysis. The mean 
age at recruitment was 63± 4.4 years and the mean BMI at 
baseline was 26.4± 4.4 kg/m2. The mean age at diagnosis was 
63.5± 10.5 years since the last cohort of women was entered 
into the MSP at 69 years of age in 2006; they were followed 
until the age of 74 years. The median time between the first 
mammogram and diagnosis of BC was 27 months (range, 
0–73 months), considering both prevalent and interval can-
Table 2. Characteristics of the final study population, subdivided by age 











<18.5     30 (0.6)     22 (0.4)     27 (0.7)     79 (0.6)
18.5–24.9 2,518 (45.7) 1,980 (40.2) 1,685 (39.7)   6,183 (42.1)
25–29.9 2,013 (36.5) 1,976 (40.1) 1,773 (41.7)   5,762 (39.2)
≥30     949 (17.2)    949 (19.3)    762 (17.9)   2,660 (18.1)
Total 5,510 (37.5) 4,927 (33.6) 4,247 (28.9) 14,684 (100)
BMI=body mass index.
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cers. The average observation time of the cohort was 70.61 
months. The total observation time was 86,442 person-years. 
During the 6-year follow-up period, 905 screen-detected can-
cers occurred (nonmelanoma skin cancers were excluded) in 
women aged 55 to 69 years who were not included in our 
study. Among women weighed during the study period, 366 
cases of BC were registered, of which 308 were invasive BC 
and 58 were in situ BC. Among the 366 BC cases, 139 were in 
the normal-weight group, 149 in the overweight group, and 
78 in the obese group. No BC cases were registered in the un-
derweight group of women. The mean interval between the 
first mammogram and diagnosis of BC was significantly lon-
ger in the normal-weight patients (31 months) compared with 
overweight (25 months) and obese (28 months) women 
(p= 0.030).
Table 3 shows the RR of BC according to BMI, adjusted for 
age. Compared with normal-weight women (RR= 1), the RRs 
for overweight and obese women were 1.17 and 1.32, respec-
tively (95% CIs, 0.92–1.47 and 1.00–1.75, respectively). When 
BMI was entered into the model as a continuous variable, the 
estimated RR associated with a linear trend for BMI was 1.21 
(95% CI, 1.05–1.40).
Tumor characteristics
A comparison between 905 patients diagnosed by the MSP 
who were not included in our study and 366 patients diag-
nosed who were included in the study is shown in Table 4. Pa-
tients diagnosed within the study had an increased tumor size 
and were more frequently axillary node-positive.
The analysis of the tumor characteristics in relation to BMI 
(Table 5) showed that obese women had a higher percentage 
of larger tumors (27% of tumors were > 2 cm) compared with 
overweight women (8.1%) and normal-weight women 
(10.7%) (p= 0.002, obese vs. overweight and normal-weight 
women). Obese women also had higher percentages of node-
positive cancers (38.5% of tumors were node-positive) com-
pared with overweight women (21%) and normal-weight 
women (22.9%) (p= 0.040, obese vs. overweight and normal-
Table 3. Relative risk of breast cancer according to body mass index of 14,684 women
Mean±SD No. of BC Population (%) RR 95% CI p-value
BMI (kg/m2), categorical
   <18.5 16.2±1.3     0    79 (0.6)              0 - -
   18.5–24.9 22.6±2.2 139 6,183 (42.1) 1.0 - -
   25–29.9 27.2±1.4 149 5,762 (39.2)   1.17 0.92–1.47 0.180
   ≥30 33.5±3.2   78 2, 660 (18.1)   1.32 1.00–1.75 0.040
BMI, continuous* - - -   1.21 1.05–1.40 0.008
BMI=body mass index; BC=breast cancer; RR=relative risk; CI=confidence interval.
*Linear trend.
Table 4. Comparison on histopathology characteristics between cases 
diagnosed in study population and all cases S-D aged 50–69 years di-
agnosed in period 2004–2006 in province of Modena
Characteristic
Cases by 
population in study 
(n=366) 
No. (%)
All cases  S-D 
diagnosed in period 
2004–2006 
by MCR (n=905) 
No. (%)
p-value
Tumor diameter (mm)* 13±2 12±1 0.790
Missing value (%) 9.3 16.3
T stage 0.029
   Tis   57 (15.6) 195 (21.5)
   T1 mic-a-b 124 (33.9) 320 (35.4)
   T1c 131 (35.8) 301 (33.3)
   T2  44 (12.0)  65 (7.2)
   T3–T4  4 (1.1)  10 (1.1)
   TX  6 (1.6)  14 (1.5)
N stage 0.010
   N0 254 (69.4) 651 (71.9)
   N1   71 (19.4) 125 (13.8)
   >N1 22 (6.0) 45 (5.0)
   NX 19 (5.2) 84 (9.3)
M staging 0.730
   M0 362 (98.9) 896 (99.1)
   M1  4 (1.1)  8 (0.9)
Grading 0.750
   I   38 (10.4) 117 (12.9)
   II 179 (48.9) 409 (45.2)
   III 134 (36.6) 312 (34.5)
   Unknown 15 (4.1) 67 (7.4)
Ki-67 (%) 0.130
   ≤20 242 (66.1) 568 (62.8)
   >20   67 (18.3) 152 (16.8)
   Unknown   57 (15.6) 185 (20.4)
Hormonal status 0.140
   ER+/PR+ 272 (73.2) 650 (71.8)
   ER+/PR– 14 (4.1) 53 (5.9)
   ER–/PR+  2 (0.5)  6 (0.7)
   ER–/PR–  32 (9.3) 54 (6.0)
   Unknown   46 (12.8) 142 (15.7)
Data are presented as number (%).
S-D=screen-detected; MCR=Modena Cancer Registry; ER=estrogen re-
ceptor; PR=progesterone receptor.
*Mean±SD.
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weight women). Data on human epidermal growth factor re-
ceptor 2 status were lacking in most cases because at that time 
it was not routinely tested.
Regarding hormone receptor status, all BMI groups had a 
higher percentage of estrogen receptor (ER) positive and pro-
gesterone receptor (PR) positive tumors (73.6% in normal-
weight, 72.3% in overweight, and 79.5% in obese women) 
compared with the other three tumor receptor categories, but 
the results were not statistically significant. Particularly, a 
Poisson regression analysis between different categories of BMI 
and hormonal receptor status showed that obesity represented 
a statistically significant risk factor for hormonal receptor-
positive BC compared with hormonal receptor-negative BC 
in which no differences were seen among the three groups of 
patients (data not shown). A multivariate analysis evaluating 
the normal-weight women as the reference category and stage 
and hormonal receptor status as covariates showed that obese 
women more frequently had an advanced stage (higher than 
stage I) of disease (p= 0.003) (Table 6).
Tumor treatments
Among 366 BC cases diagnosed in the study, 102 patients 
(27.9%) were treated with chemotherapy and 265 (72.1%) 
with hormonal treatment. A statistically nonsignificant trend 
of increased use of chemotherapy was shown for obese pa-
tients compared with normal and overweight patients (35.9% 
vs. 25% and 26.3%, respectively, p= 0.237), consistent with the 
more advanced stage of disease in this group of women. No 
statistically significant differences were seen for hormonal 
treatment, although a trend in favor of obese women was 
shown (78.2% vs. 67.9% for normal-weight and 73.6% for 
overweight women, respectively, p= 0.300). Among the dif-
ferent chemotherapy regimens used, anthracycline-based 
treatments represented the most frequently adopted regimen 
(52.0%), followed by taxane-based regimens (32.5%), cyclo-
phosphamide/methotrexate/fluorouracil (9.7%), and others 
(5.8%). This distribution of regimens reflects the era in which 
anthracycline represented the milestone of BC chemotherapy. 









Tumor diameter (mm)* 13±2 11±1 17±3 0.002
T stage 0.002
   Tis 25 (17.9) 23 (15.5) 9 (11.5)
   T1 mic-a-b 45 (32.1) 62 (42.0) 17 (21.8)
   T1c 50 (35.7) 50 (33.8) 31 (39.7)
   T2 13 (9.3) 12 (8.1) 19 (24.4)
   T3–T4 2 (1.4) 0 2 (2.6)
   TX 5 (3.6) 1 (0.7) 0
N stage† 0.040
   N0 97 (69.3) 111 (75.0) 46 (59.0)
   N1 26 (18.6) 22 (14.9) 23 (29.5)
   >N1 6 (4.3) 9 (6.1) 7 (9.0)
   NX 11 (7.9) 6 (4.1) 2 (2.6)
M stage 0.210
   M0 137 (98.0) 148 (100) 77 (99)
   M1 3 (1.4) 0 1 (0.3)
Grading 0.480
   I 17 (12.3) 15 (10.1) 6 (7.7)
   II 66 (47.8) 75 (50.7) 38 (48.7)
   III 47 (34.1) 54 (36.5) 33 (42.3)
   Unknown 8 (5.8) 4 (2.7) 1 (1.3)
Ki-67 (%) 0.130
   ≤20 96 (68.6) 95 (64.2) 51 (65.4)
   >20 19 (13.6) 28 (18.9) 20 (25.6)
   Unknown 25 (17.9) 25 (16.9) 7 (9.0)
Hormonal status 0.950
   ER+/PR+ 103 (73.6) 107 (72.3) 62 (79.5)
   ER+/PR–  6 (4.3) 6 (4.1) 2 (2.6)
   ER–/PR+ 1 (0.7) 1 (0.7) 0
   ER–/PR– 11 (7.9) 14 (9.5) 7 (9.0)
   Unknown 19 (13.6) 20 (13.5) 7 (9.0)
Data are presented as number (%).
BMI=body mass index; ER=estrogen receptor; PR=progesterone receptor.
*Mean ±SD (34 missing value);†N0 =N0+N0i; N1 =N1+N1mic+N1a; 
>N1=N2+N2a+N3.
Table 6. Multivariate logistic model on 366 breast cancer cases
BMI category (kg/m2) HR 95% CI p-value
Overweight (25–29.9)
   Receptor status
      ER+/PR+ Ref. - -
      Other receptor status* 1.09 0.54–2.18 0.798
   Age at diagnosis 
      59±5.3 yr (normal weight) Ref. - -
      62±4.6 yr 1.02 0.96–1.07 0.529
   Stage
      I Ref. - -
      II 0.65 0.35–1.20 0.175
      III 0.75 0.28–2.00 0.567
Obese ≥30
   Receptor status
      ER+/PR+ Ref. - -
      Other receptor status* 0.91 0.38–2.19 0.840
   Age at diagnosis
      59±5.3 yr (normal weight) Ref. - -
      63±5.2 yr 1.04 0.97–1.11 0.185
   Stage
      I Ref. - -
      II 2.79 1.42–5.49 0.003
      III 2.33 0.81–6.71 0.115
BMI =body mass index; HR =hazard ratio; CI =confidence interval; ER = 
estrogen receptor; PR=progesterone receptor; Ref.= reference category.
*Other receptor status=ER+/PR–; ER–/PR+; ER–/PR–.
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Finally, among hormonal treatments, aromatase inhibitors 
were the most used drugs (74.3%), with the remaining thera-
py consisting of tamoxifen (25.7%).
Event-free survival
After 104 months from the first BC diagnosis, with a medi-
an follow-up period of 65 months (range, 2–104 months), we 
observed 46 events, including 11 BC recurrences (local and 
distant), 16 second BC tumors, and 19 other second malig-
nancies. We observed four BC recurrences in obese women, 
four in overweight women, and three in normal-weight women, 
without statistical significance (p= 0.440). No differences were 
seen for second BC tumors, but a significantly higher rate of 
other second malignancies occurred in obese patients, who 
developed two colon, one endometrium, one pancreas, two 
lung, one melanoma, and one hematological (leukemia) 
malignancy. In total, the rate of events was higher in obese than 
in non-obese women (17.9% of obese BC patients developed 
events, p= 0.032) (Table 7).
The 5-year EFS was 80.0%, 89.0%, and 89.0% among the 
obese, overweight, and normal-weight women, respectively 
(p= 0.200) (Figure 2).
DISCUSSION
We examined BC incidence, recurrence, and second tumor 
development in relation to BMI in our study population. In 
this large cohort study of women aged 55 to 69 years partici-
pating in the MSP, obese women showed an increased risk for 
BC compared with normal-weight and overweight women 
This study also confirms that BC tumors in obese women are 
likely to be larger and more frequently node-positive than 
those in other groups of patients. Furthermore, obese women 
develop more second events, particularly second non-BC tu-
mors. Finally, this study shows an unfavorable prognosis of 
obese patients in terms of developing BC recurrences and 
other tumors at 5 years of follow-up, even though the differ-
ences were not significant in our study.
The association between measures of body size and risk of 
BC has been confirmed in numerous studies [2-4,18]. In gen-
eral, obesity has been found to be positively associated with a 
higher risk and a poorer prognosis of postmenopausal BC 
[12,19]. To establish with acceptable certainty that all partici-
pants were postmenopausal, we considered in this study only 
women aged 55 to 69 years.
Our findings are compatible with those of previous studies 
[1-4,12-14,18,19], where a positive association between BMI 
and risk of postmenopausal BC was seen. Indeed, the RR for 
postmenopausal BC among obese women was significantly 
higher than that for normal-weight women.
Moreover, we found that obese women were more likely to 
present with a larger tumor size compared with normal-
weight women, and the difference was statistically significant. 
The present finding is consistent with other study results 
showing an association of obesity with tumors with poor 
prognostic characteristics; in fact, all of those studies found 
that an increased BMI or other measures of adiposity were 
significantly associated with an increased risk of cancer stage 
being higher than stage II (according to the American Joint 
Committee on Cancer staging system) and with an increased 
frequency of grade III tumors [20-22].
Several studies have examined whether the risk of post-
menopausal BC associated with obesity is heterogeneous 
according to ER/PR status [23-25]. In our study, we observed 
an increased risk of ER and PR positive tumors in all BMI cat-
egories examined. Other data suggest an increase in receptor-
positive BC in obese women [23-25], and the current study 
may show a trend in that direction, but it was not statistically 
Table 7. Distribution of second events in relation to body mass index of 












Recurrence  3 (2.1) 4 (2.7) 4 (5.1) 0.440
Second breast cancer 10 (7.2) 4 (2.7) 2 (2.5) 0.120
Other second malignancies  2 (1.4) 9 (6.0)   8 (10.2) 0.016
Total events 15 (10.8) 17 (11.4) 14 (17.9) 0.032
BMI=body mass index.
Figure 2. Five-year event-free survival (EFS) among obese, overweight 
and normal-weight women. EFS for normal weight (blue line) and over-
weight (green line) patients was equal to 89.0%. Patients with obesity 
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significant, perhaps owing to a relatively small sample size or 
relatively short duration of follow-up.
The more advanced stage at diagnosis and the more biologi-
cally aggressive tumors can explain why obese BC patients 
have a worse prognosis, since they are more likely to develop 
local and distant recurrences.
We demonstrated that obesity was associated with an in-
creased risk of a second event. Particularly, a statistically sig-
nificant association was found for second non-BC tumors. 
Because a second BC tumor represents the most frequent tu-
mor occurring after primary BC [26,27] in all patients affect-
ed, no differences were seen between different groups of pa-
tients for this event probably because of the small number of 
cases. Indeed, colorectal, endometrial, and pancreatic cancers, 
which are more represented in the obese patient group, are 
considered as related to BMI, as demonstrated in a prospec-
tive cohort study of over 1 million women [14]. In this study, 
Reeves et al. [14] showed an association between increased 
BMI and an increased incidence of endometrial cancer (trend 
in RR per 10 units, 2.89; 95% CI, 2.62–3.18), pancreatic can-
cer (1.24, 1.03–1.48), and colorectal cancer (1.61, 1.05–2.48) 
in premenopausal women.
The 5-year EFS curve shows only a negative trend for obese 
patients without reaching statistical significance, probably be-
cause many second events occurred in the last 3 years of fol-
low-up. Moreover, there are many late recurrences of receptor-
positive BC and a 5-year follow-up may be too short to accu-
rately determine the overall relapse rate, which could in turn 
ultimately affect the survival curves. A further explanation is 
that the lack of increased risk of BC recurrence and a second 
BC could have been influenced by the hormonal adjuvant 
treatment received by patients because the majority had a 
hormone-dependent BC. In any case, our findings are broadly 
consistent with those of previous studies showing that patients 
with BC who are obese demonstrate a poor prognosis [8,10-
12,14]. Particularly, in a systematic review of numerous stud-
ies collectively incorporating more than 29,000 women with 
invasive BC, Chlebowski et al. [9] showed a statistically signif-
icant increased risk of disease recurrence and mortality in 
obese women compared with lean women, with hazard ratios 
ranging from 1.3 to well over 2.
The primary strength of this study is the prospective design, 
which gave us the ability to examine, with adequate statistical 
power, the association between BMI and the risk of BC in 
postmenopausal women. To our knowledge, no previous 
study has examined the role of BMI in the incidence of BC in 
a large Italian cohort of postmenopausal women.
Moreover, our evaluation of the relationship between BMI 
and BC incidence in women participating in the MSP sup-
ports emerging considerations of screening program locations 
as one of the first possible settings for cancer prevention and 
education.
Finally, we note that our study was made possible and facili-
tated only by the existence of a population-based cancer regis-
try in the area. Through the registry, we recognized all new 
cases of cancers in women aged 55 to 69 years and obtained 
information about their follow-up status. We consider a can-
cer registry an important tool for adequate monitoring of 
screening programs.
This study has several limitations. A weakness is that meno-
pausal status was assessed based only on age criteria. Because 
we did not collect data on the menopausal status, we included 
only women aged 55 to 69 years in view of the fact that the 
median age at menopause in Europe ranges from 50.1 to 52.8 
years [28]. Moreover, because the results are from a popula-
tion of predominantly white middle-aged or elderly women, 
they may not be generalizable to other populations of interest.
However, considering that according to the MCR data, 
approximately 60% of BC arises in women aged 55 to 69 and 
70% of these patients adhere to the MSP, our data could reflect 
approximately half of the BC population. Furthermore, no 
baseline characteristics were collected from women not 
entered into the study, which could represent a selection bias, 
although a comparison with the “Progressi delle Aziende 
Sanitarie per la Salute in Italia” study seems to correlate with 
our data regarding the percentage of overweight and obese 
women (57.8%) among the general population aged 50 to 69 
years [16]. Younger or older women have to be better investi-
gated to explore other risk factors and BMI conditions at that 
age. Another limitation is the potential for measurement error 
from self-reported height, although the correlation of self-
reported height with measured height has been reported to be 
high, ranging from 0.80 to 0.95 [29,30].
Another limitation of the study is that body weight was 
measured only at the mammography examination and may 
not reflect the weight at diagnosis or recurrence, because pa-
tients may have lost or gained weight at that time. Moreover, 
the sample size of 366 women with BC is small for the out-
come analysis.
Finally, because information on the potential confounders 
(e.g., reproductive and menstrual history and hormone re-
placement therapy use) was not available, it was not possible 
to calculate adjusted RRs.
In conclusion, despite the limitations described above, we 
observed a significantly higher risk of postmenopausal BC 
and a higher rate of second events in obese women in the 
Province of Modena.
Our findings support the evidence that obesity, however 
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measured, adversely affects the development of BC. Further-
more, obese women represent a group of patients at risk for 
other obesity-related cancers, such as colorectal, endometrial, 
and pancreatic cancer. Obesity is one of the few risk factors 
for BC that can be modified throughout life. Thus, a continu-
ous surveillance of the effect of BMI on BC incidence and 
prognosis is needed. Finally, weight management should be 
an integral part of BC screening and prevention strategies.
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